Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Interventional × Paraganglioma × lanreotide × Clear all

Phase

Status

Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Endocrine 1 CNS 1

Conditions

Neuroendocrine Tumors 11 Carcinoid Tumor 5 Acromegaly 3 Serotonin Syndrome 2 Pituitary Neoplasms 2 Gastro-enteropancreatic neuroendocrine tumor 2 Prostatic Neoplasms 1 Pheochromocytoma 1 Peritoneal Neoplasms 1 Paraganglioma 1 Pancreatic Neoplasms 1 Neuroendocrine Tumour With Carcinoid Symptoms 1 Neuroendocrine Tumors in Lung 1 Neoplasms 1 Neoplasm Metastasis 1 Intestinal Obstruction 1 Growth Hormone-Secreting Pituitary Adenoma 1 Gigantism 1 Gastrointestinal Neoplasms 1 Flushing 1 Endocrine Tumors 1 Diarrhea 1 Carcinoma, Merkel Cell 1 Carcinoma, Hepatocellular 1 Carcinoma 1 Carcinoid Heart Disease 1 Adenoma, Islet Cell 1

Interventions

lutetium Lu 177 dotatate 6 gallium Ga 68 dotatate 5 Specimen Handling 4 Magnetic Resonance Spectroscopy 4 Temozolomide 3 3-Iodobenzylguanidine 3 olaparib 2 belzutifan 2 anlotinib 2 Phenoxybenzamine 2 Nivolumab 2 Fluorodeoxyglucose F18 2 Everolimus 2 Biopsy 2 3-fluorobenzylguanidine 2 177Lu-octreotide, DOTA(0)-Tyr(3)- 2 talazoparib 1 spartalizumab 1 pazopanib 1 lanreotide 1 guadecitabine 1 fludarabine phosphate 1 copper dotatate CU-64 1 cixutumumab 1 cabozantinib 1 atezolizumab 1 Sunitinib 1 Salts 1 Radiosurgery 1 Octreotide 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03946527 2026-03-02

LAMPARA

Columbia University

Phase 2 Active not recruiting

Paraganglioma, Pheochromocytoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡